NeOnc Technologies Holdings, Inc. (NTHI) is a Calabasas, California-based clinical-stage biopharmaceutical company developing drugs for aggressive brain cancers. Its lead candidates are NEO100, an intranasal formulation of purified perillyl alcohol in Phase 2a testing, and NEO212, an oral temozolomide-perillyl alcohol conjugate. The company has no meaningful product revenue and is valued largely on the probability-weighted success of those programs.
In Thursday's session, the stock dropped 12.98% to $3.62, down from the prior session's close of $4.16. The move confirms a bearish short-term shift: the shares are now 26% below Friday's close of $4.91 and are testing their 20-day moving average, even as they remain roughly 34% above mid-October levels. No verified negative catalyst was found for the decline; the selling is most consistent with profit-taking after a sharp, news-driven advance.
No verified news or fundamental catalyst found in company releases, regulatory filings, or wire reports explains Thursday's decline. There was no earnings release, no guidance revision, no analyst downgrade, and no disclosed financing on the day. The most recent item of substance was a Roth MKM reiteration of a Buy rating and $20 target on November 18, and a company statement the same day confirming the chief executive's continued open-market purchases, which now exceed 371,000 shares and $1.5 million this year. Both are constructive, not bearish.
The more plausible explanation is mechanical. The stock nearly doubled off its October 16 close of $2.70, peaking at a $5.44 intraday high on November 16, leaving it vulnerable to profit-taking, particularly with a relative strength index in the high 50s after having been deeply overbought. That reversed into consecutive losses of 7.54%, 4.63%, and 3.93% before Thursday's acceleration, a pattern consistent with a momentum unwind rather than a fundamental shock. The company also entered the week with a full calendar — updated NEO100 Phase 1/2a and NEO212 Phase 1 data presented at the Society for Neuro-Oncology annual meeting on November 13, and a scheduled FDA End-of-Phase 1 meeting for NEO212 on November 17 — creating an unusually high bar for "sell the news" disappointment once the events passed without a headline-grabbing update. Thin liquidity amplifies such moves: with a float of roughly 9.6 million shares and average volume near 201,000 shares, modest sell orders can move the price by several percentage points.
The pullback is easier to understand against the rally it followed. In early November the company reported final Phase 2a results for intranasal NEO100 in recurrent IDH-mutant high-grade glioma, including a six-month progression-free survival rate of 48.9% against a 20% benchmark and median overall survival of 26.1 months. On November 11 it disclosed that the FDA had granted a Type B End-of-Phase meeting in early January 2027 to discuss a potential accelerated approval pathway and the design of a confirmatory Phase 3 trial. Four analysts now carry a Strong Buy consensus with an average target of $17, and NEO100 and NEO212 are modeled for launch in 2029 and 2030 respectively. That is a genuinely stronger fundamental story than the stock had in October — which is precisely why some holders chose to monetize it.
Turnover during the four-session slide has run modestly above the 20-day average of about 201,000 shares, with 282,000 shares on November 16, 264,000 on November 17, and 280,000 on November 18 — elevated but well short of the panic volumes seen on the September 8 and September 15 declines. Short interest of roughly 921,000 shares, or 3.3% of shares outstanding, has crept higher but is not large enough to suggest a covering-driven squeeze in either direction.
Technically, the stock is testing its 20-day moving average near $3.64, with the 50-day average at $3.30 as the next reference point and the 200-day average far above at $5.15. The shares remain in a broader downtrend from the 52-week high of $11.38, and the November rally failed below that long-term average. The move appears company-specific rather than sector-driven, with no obvious peer or index catalyst aligning with the timing.
The score runs from 0, meaning no meaningful news and a move that is normal for the stock, to 100, meaning transformative news and an extreme, rare price move. This event scores 20 out of 100.
The verified news was real but not decisive: positive Phase 2a data, an FDA meeting grant, insider purchases, and analyst support form a constructive backdrop, yet none of it was new on Thursday, and none carried the materiality to justify a double-digit decline on its own. The price move, while sharp, was only about 2.5 times the stock's average absolute daily change of roughly 5.1% over the past 60 sessions, and moves of similar or greater size occurred five times in that window. A modest news signal combined with a familiar magnitude of volatility produces a low score.
Attention now shifts to the FDA Type B End-of-Phase meeting in early January 2027, where the company will seek clarity on whether its data can support an accelerated approval filing for NEO100 in recurrent IDH-mutant grade 4 astrocytoma and on the design of a randomized Phase 3 trial with overall survival as the primary endpoint. Management has cautioned that a scheduled meeting does not imply regulatory agreement on the development plan or an approval pathway. Formal Phase 2 plans for NEO212 following the November 17 meeting are the other near-term disclosure to watch.
Financially, the company ended the September quarter with $6.17 million in cash, a current ratio of 0.38, and a quarterly net loss of $4.44 million — a combination that keeps capital-raising risk firmly on the radar and makes dilution a recurring consideration for shareholders. Next quarterly results are expected in the spring. Key risks include single-arm trial limitations, the possibility that confirmatory data fail to replicate Phase 2a results, and the binary nature of regulatory outcomes for unapproved drug candidates.
Tickeron's Trending AI Robots page offers a curated view of the platform's strongest automated trading strategies, drawn from a library of hundreds of AI trading bots that cover thousands of tickers. Because bots vary widely by strategy, holding timeframe, performance metrics, and traded symbols, the featured list highlights only those showing the best results under present market conditions. Reviewing it can help traders identify approaches that match their own risk tolerance and objectives.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The 10-day RSI Indicator for NTHI moved out of overbought territory on November 17, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 4 instances where the indicator moved out of the overbought zone. In 4 of the 4 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 14 of 14 cases where NTHI's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NTHI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
NTHI broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on NTHI as a result. In 23 of 26 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 88%.
The Moving Average Convergence Divergence (MACD) for NTHI just turned positive on October 16, 2026. Looking at past instances where NTHI's MACD turned positive, the stock continued to rise in 9 of 11 cases over the following month. The odds of a continued upward trend are 82%.
NTHI moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for NTHI crossed bullishly above the 50-day moving average on November 10, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 4 of 4 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +8.63% 3-day Advance, the price is estimated to grow further. Considering data from situations where NTHI advanced for three days, in 67 of 77 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
The Aroon Indicator entered an Uptrend today. In 39 of 41 cases where NTHI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. NTHI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 57 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 84 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-5.425) is normal, around the industry mean (3.596). P/E Ratio (-1.646) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (1666.667) is also within normal values, averaging (443.347).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NTHI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology